KMC becomes first in Qatar to offer stem cell therapy to public
Tribune News Network
Doha
The Korean Medical Center (KMC) has officially launched Qatar's first widely accessible stem cell therapy programme, offering a groundbreaking, non-surgical treatment for early-stage joint degeneration.
While stem cell therapy has previously been available only to niche groups, this marks the first time any eligible patient can undergo live stem cell therapy in the country.
Led by Dr. Youngwoong Back, head of the Spine and Joint Center at KMC, the programme offers a minimally invasive alternative to joint replacement for patients suffering from cartilage defects, early-stage osteoarthritis, or ligament injuries.
The treatment uses live stem cells extracted from the patient's own bone marrow, injected directly into the affected joint to halt further cartilage deterioration and relieve pain.
'One of the biggest misconceptions I see is that people wait until the pain is unbearable before they seek treatment,' said Dr. Back. 'But by then, we're often dealing with advanced, irreversible degeneration. Stem cell therapy isn't about turning back time, it's about intervening early, when the body still has the biological capacity to respond.'
'By harvesting mesenchymal stem cells from the patient's own bone marrow and reinjecting them into damaged joints, we aim to halt the inflammatory cascade that leads to cartilage erosion.These cells do not rebuild cartilage from scratch, but they create a supportive environment that promotes tissue stabilisation, reduces inflammation, alleviates pain, and slows down further degeneration. It's not a miracle—it's science applied with precision and timing. For patients in the early and middle stages, this could mean the difference between preserving years of mobility and facing inevitable surgical intervention,' he added.
With over 13 years of experience, Dr. Back is a Korean board-certified orthopaedic surgeon affiliated with South Korea's prestigious Asan Medical Center.
He is a member of the Korean Society of Stem Cell and Regenerative Medicine and has advanced his training in orthopaedic care at the Mayo Clinic (USA) and across the UAE. At KMC, he now brings this expertise to Qatar, tailoring treatments to Qatar's growing demand for preventative and regenerative joint care.
What sets KMC's stem cell therapy apart is its accessibility, precision, and scientific credibility. For the first time in Qatar, live stem cell therapy is accessible to the public. While the treatment is especially effective for individuals with early and middle-stage joint degeneration, such as those diagnosed with Kellgren-Lawrence Grade 2 or 3, it is not restricted to them. This broad availability marks a major shift in how regenerative care is delivered in the country.
The therapy itself is a game-changer. It is a needle-based procedure performed without general anaesthesia or the need for an operating room. Bone marrow is extracted from the patient's pelvic bone, and live stem cells are reinjected into the affected joint, helping to halt cartilage breakdown. Most patients report no pain during the injection and only mild discomfort on the donor site the following morning.
Backed by scientific partnerships with EHL Bio and GC Genome, Korea's leaders in regenerative research, KMC's approach ensures that global innovation meets local care. Results speak for themselves: over 90 to 95 percent of patients with early-stage joint degeneration who underwent stem cell therapy reported significant pain relief and restored mobility within weeks.
For the first time, cutting-edge stem cell therapy is no longer out of reach—it's right here in Qatar, ready to change lives.
'This is not just a medical first, it's a statement of intent,' said Dr. Fatih Mehmet Gul, CEO, Korean Medical Center. 'By making stem cell therapy immediately available to the public, we're setting a new benchmark for what healthcare access should look like in Qatar and the region. For too long, regenerative treatments have been confined to niche cases. KMC changes that.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Qatar Tribune
7 hours ago
- Qatar Tribune
Qatar, UK hold joint working group meeting on health sector cooperation
Tribune News Network Doha The Ministry of Public Health (MoPH) and the UK Department of Health and Social Care convened a Joint Working Group meeting via video conference to strengthen bilateral cooperation in key areas of healthcare. The Qatari delegation was led by Assistant Minister of Public Health for Health Affairs, HE Dr Salih Ali Al Marri, while the British side was headed by Fionn Craig, Deputy Director of Bilateral Relations and Trade. Discussions focused on antimicrobial resistance, artificial intelligence (AI) and data use in healthcare, the resilience of medical supply chains, and enhancing patient safety and quality of care. The meeting featured a comprehensive review of Qatar's national programme for combating antimicrobial resistance, pharmaceutical security measures, and strategies for securing antibiotics. The UK side shared updates on its post-UN General Assembly initiatives, including the establishment of an independent scientific committee on antimicrobial resistance. Both sides also explored advancements in digital health. Qatar presented the Qatar Health Information Exchange Platform and outlined its approach to workforce development and private sector collaboration. The UK highlighted its ten-year plan to shift to digital systems, as well as ethical and regulatory frameworks for AI integration in healthcare. Supply chain resilience and the role of AI in healthcare logistics were also examined, alongside Qatar's national framework for patient safety and capacity-building efforts. The UK delegation provided insights into its Health Services Safety Investigations Body (HSSIB), patient safety networks, and human factors expertise. The meeting concluded with a shared commitment to continued dialogue and collaboration in pursuit of safer, smarter, and more resilient healthcare systems.
Qatar Tribune
7 hours ago
- Qatar Tribune
QRCS, OCHA launch nutrition programme in Syria
Tribune News Network Doha With funding from the United Nations Office for the Coordination of Humanitarian Affairs (OCHA), the Qatar Red Crescent Society (QRCS) has launched a project aimed at improving access to comprehensive nutrition, and infant and young child feeding services during emergencies. The overall objective of the project is to save lives and reduce mortality and morbidity rates among the most vulnerable groups in northwestern Syria, particularly under-five children and pregnant and lactating women in conflict-affected areas. To ensure the early detection of acute malnutrition, the project involves screening, provision of preventive nutritional supplements, and referral of severe and complicated cases to specialised therapy centres. Also, community-based nutrition services are provided in accordance with the approved protocols and standard operation procedures in emergencies. Comprising 48 health workers in total, nine rapid response teams (RRTs) and 15 mobile teams are deployed to reach out to conflict-affected populations in the remotest and most vulnerable areas. At the same time, the project adopts interactive and community-based awareness-raising techniques that promote proper health and nutrition behaviours, thus ensuring a sustainable post-execution impact. The project is expected to reach out to more than 212,000 direct beneficiaries in 26 villages and camps for internally displaced persons (IDPs), including approximately 80,000 children and 60,000 pregnant or breastfeeding women. This includes the provision of health consultations and information on maternal and child nutrition in emergencies, treatment of moderate and severe malnutrition, and provision of reproductive health services when needed.
Qatar Tribune
7 hours ago
- Qatar Tribune
KMC becomes first in Qatar to offer stem cell therapy to public
Tribune News Network Doha The Korean Medical Center (KMC) has officially launched Qatar's first widely accessible stem cell therapy programme, offering a groundbreaking, non-surgical treatment for early-stage joint degeneration. While stem cell therapy has previously been available only to niche groups, this marks the first time any eligible patient can undergo live stem cell therapy in the country. Led by Dr. Youngwoong Back, head of the Spine and Joint Center at KMC, the programme offers a minimally invasive alternative to joint replacement for patients suffering from cartilage defects, early-stage osteoarthritis, or ligament injuries. The treatment uses live stem cells extracted from the patient's own bone marrow, injected directly into the affected joint to halt further cartilage deterioration and relieve pain. 'One of the biggest misconceptions I see is that people wait until the pain is unbearable before they seek treatment,' said Dr. Back. 'But by then, we're often dealing with advanced, irreversible degeneration. Stem cell therapy isn't about turning back time, it's about intervening early, when the body still has the biological capacity to respond.' 'By harvesting mesenchymal stem cells from the patient's own bone marrow and reinjecting them into damaged joints, we aim to halt the inflammatory cascade that leads to cartilage cells do not rebuild cartilage from scratch, but they create a supportive environment that promotes tissue stabilisation, reduces inflammation, alleviates pain, and slows down further degeneration. It's not a miracle—it's science applied with precision and timing. For patients in the early and middle stages, this could mean the difference between preserving years of mobility and facing inevitable surgical intervention,' he added. With over 13 years of experience, Dr. Back is a Korean board-certified orthopaedic surgeon affiliated with South Korea's prestigious Asan Medical Center. He is a member of the Korean Society of Stem Cell and Regenerative Medicine and has advanced his training in orthopaedic care at the Mayo Clinic (USA) and across the UAE. At KMC, he now brings this expertise to Qatar, tailoring treatments to Qatar's growing demand for preventative and regenerative joint care. What sets KMC's stem cell therapy apart is its accessibility, precision, and scientific credibility. For the first time in Qatar, live stem cell therapy is accessible to the public. While the treatment is especially effective for individuals with early and middle-stage joint degeneration, such as those diagnosed with Kellgren-Lawrence Grade 2 or 3, it is not restricted to them. This broad availability marks a major shift in how regenerative care is delivered in the country. The therapy itself is a game-changer. It is a needle-based procedure performed without general anaesthesia or the need for an operating room. Bone marrow is extracted from the patient's pelvic bone, and live stem cells are reinjected into the affected joint, helping to halt cartilage breakdown. Most patients report no pain during the injection and only mild discomfort on the donor site the following morning. Backed by scientific partnerships with EHL Bio and GC Genome, Korea's leaders in regenerative research, KMC's approach ensures that global innovation meets local care. Results speak for themselves: over 90 to 95 percent of patients with early-stage joint degeneration who underwent stem cell therapy reported significant pain relief and restored mobility within weeks. For the first time, cutting-edge stem cell therapy is no longer out of reach—it's right here in Qatar, ready to change lives. 'This is not just a medical first, it's a statement of intent,' said Dr. Fatih Mehmet Gul, CEO, Korean Medical Center. 'By making stem cell therapy immediately available to the public, we're setting a new benchmark for what healthcare access should look like in Qatar and the region. For too long, regenerative treatments have been confined to niche cases. KMC changes that.'
